Combining Molecularly Targeted Agents: Is More Always Better?
Loading...
Embargo End Date
ICR Authors
Authors
Sundar, R
Valeri, N
Harrington, KJ
Yap, TA
Valeri, N
Harrington, KJ
Yap, TA
Document Type
Journal Article
Date
2017-03-01
Date Accepted
2016-10-11
Abstract
The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1123-5. ©2016 AACRSee related article by Calvo et al., p. 1177.
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (5), pp. 1123 - 1125
Rights
Source Title
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
1078-0432
eISSN
1557-3265
Research Team
Medicine Drug Development Unit (de Bono)
Gastrointestinal Cancer Biology and Genomics
Targeted Therapy
Gastrointestinal Cancer Biology and Genomics
Targeted Therapy